| Treating diabetes today with gliclazide MR: a matter of numbers. | |
| | |
MedLine Citation:
|
PMID: 22118706 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by worsening hyperglycaemia. Lowering haemoglobin A1c to below or around 7% has been shown to reduce microvascular and neuropathic complications of diabetes. The ongoing uncertainty regarding whether intensive glycaemic control can reduce the increased risk of cardiovascular disease (CVD) in people with T2DM stirred the launch of the recent long-term megatrials. These trials compared the effects of intensive vs. standard control on vascular complications in relatively high CV risk participants with T2DM. While in Veterans Affairs Diabetes Trial, and Action to Control Cardiovascular Risk in Diabetes, the effect of glucose optimization resulted either in no protection or in an excessive CVD death, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial showed that intensive glycaemic control reduced the risk of combined major macrovascular and microvascular events. In this trial, the glucose control strategy was based on gliclazide MR at randomization in all patients and then further sequential addition of other glucose-lowering drugs. Several studies showed that gliclazide has antioxidant properties, reduces markers of endothelial inflammation, and prevents glucose-induced apoptosis of endothelial cells. These positive antioxidant effects are not confined to the vascular wall but they are effective also in the β cells. These properties are important because (i) in patients with atherosclerotic process, microvascular abnormalities may hasten disease progression and (ii) slowing the microvascular complications may have a potentially remarkable effect on the natural history of macrovascular disease. |
| | |
Authors:
|
A Avogaro |
Related Documents
:
|
15579616 - Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a c... 16193096 - Insulin glulisine. 21908416 - Long-term mineralocorticoid receptor blockade ameliorates progression of experimental d... 3312936 - The influence of acute hyperinsulinemia on the insulin-related material in brain, testi... 2584876 - Nasal mucociliary clearance in patients with diabetes mellitus. 21106556 - Controversies in the cardiovascular management of type 2 diabetes. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 14 Suppl 1 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-11-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 14-9 Citation Subset: IM |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Clinical and Experimental Medicine, University of Padova, Venetian Institute of Molecular Medicine, Padova, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treating diabetes today: a matter of selectivity of sulphonylureas.
Next Document: What matters in ADVANCE and ADVANCE-ON.